We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

McNeil Healthcare (Ireland) Ltd

Airton Road, Tallaght, Dublin 24, Ireland
Telephone: +353 1 466 5200
Fax: +353 1 466 5316
Summary of Product Characteristics last updated on medicines.ie: 14/12/2017
SPC Stugeron 15mg Tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 14/12/2017 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   06-Dec-2017
Legal Category:   Supply through pharmacy only

Free-text change information supplied by the pharmaceutical company



Section 4.8 –  New text added as introductory paragraph as per below –

 

The safety of Stugeron was evaluated in 372 cinnarizine treated subjects who participated in 7 placebo-controlled, double-blind clinical trials for the indications peripheral circulatory disorders, cerebral circulatory disorders, vertigo and seasickness; and in 668 cinnarizine treated subjects who participated in 6 comparator and 13-open label clinical trials for the indications of peripheral circulatory disorders, cerebral circulatory disorders and vertigo. Based on pooled safety data from these clinical trials, the most commonly reported (>2% incidence) Adverse Drug Reactions (ADRs) were: Somnolence (8.3%) and Weight Increased (2.1%).

 

Deleted below texts –

 

The safety of STUGERON was evaluated in 167 cinnarizine-treated subjects who participated in 1 placebo controlled trial (166 placebo-treated subjects) in the prophylaxis of seasickness. In this trial, only Somnolence has been included as an ADR with an incidence of 8.4% in the cinnarizine group compared to 4.8% in the placebo group.

 

Updated with blue texts as per below as applicable

 

Including the above mentioned ADR, the following ADRs have been observed from clinical trials and post-marketing experiences reported with the use of STUGERON. Frequencies displayed use the following convention:

 

Tabulated presentation of section 4.8 updated as per below – Uncommon frequency column has been added.

Nausea, Hypersomnia, Lethargy, Hyperhidrosis, Stomach Discomfort, Vomiting; Abdominal Pain Upper; Dyspepsia, Fatigue, weight increased has been added.

Lichenoid Keratosis moved from Not known to Uncommon frequency.

Hypersensitivity, Headache, Dry mouth and Gastrointestinal disorder were deleted.

System Organ Class

Adverse Drug Reactions

Frequency Category

Common

(≥ 1/100 to < 1/10)

Uncommon

(≥1/1,000 to <1/100)

Not Known

 

Nervous System

Disorders

Somnolence

Hypersomnia; Lethargy

Dyskinesia;

Extrapyramidal Disorder;

Parkinsonism; Tremor

Gastrointestinal disorders

Nausea

Stomach Discomfort;

Vomiting; Abdominal Pain Upper; Dyspepsia

 

Skin and subcutaneous

tissue disorders

 

Hyperhidrosis; Lichenoid Keratosis

Lichen Planus;

Subacute Cutaneous Lupus Erythematosus

 

Musculoskeletal and Connective Tissue Disorders

 

 

Muscle rigidity

General Disorders and Administration Site Conditions

 

Fatigue

 

Investigations

Weight Increased

 

 

 

 

Section 10: date of revision of text is updated with 06 December 2017.

Updated on 07/08/2015 and displayed until 14/12/2017
Reasons for adding or updating:
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
Date of revision of text on the SPC:   08-Jul-2015
Legal Category:   Supply through pharmacy only

Free-text change information supplied by the pharmaceutical company

Addition of the following text to Section 4.8

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.

Updated on 21/01/2014 and displayed until 07/08/2015
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.9 - Overdose
Date of revision of text on the SPC:   13-Jan-2014
Legal Category:   Supply through pharmacy only

Free-text change information supplied by the pharmaceutical company

Section 4.4:

FROM:

As with other antihistamines, Stugeron may cause epigastric upset, which may be diminished if taken after meals.

 

Cinnarizine is a vasodilator.  While it has not been found to reduce blood pressure significantly, it should be used with caution in those with coronary artery disease or in patients with hypotension.

 

In patients with Parkinson's disease, Stugeron should only be given if the advantages outweigh the possible risk of aggravating this disease.

 

Stugeron may cause somnolence, especially at the start of treatment.  Therefore, caution should be taken when alcohol or CNS depressants are used concomitantly.

 

Because of its antihistamine effect, Stugeron may prevent otherwise positive reactions to dermal reactivity indicators if used up to 4 days prior to skin testing.

 

Use of cinnarizine should be avoided in porphyria.

 

There have been no specific studies in hepatic or renal dysfunction. Stugeron should be used with care in patients with hepatic or renal insufficiency.

 

Patients with rare hereditary problems of galactose intolerance, fructose intolerance, LAPP lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

 

Avoid alcoholic drink.

 

Warning:  Do not exceed the stated dose.

TO:

As with other antihistamines, Stugeron may cause epigastric upset, which may be diminished if taken after meals.

 

Cinnarizine is a vasodilator.  While it has not been found to reduce blood pressure significantly, it should be used with caution in those with coronary artery disease or in patients with hypotension.

 

In patients with Parkinson's disease, Stugeron should only be given if the advantages outweigh the possible risk of aggravating this disease.

 

Stugeron may cause somnolence, especially at the start of treatment.  Therefore, caution should be taken when alcohol or CNS depressants or tricyclic antidepressants are used concomitantly. (See section 4.5).

 

Diagnostic Interference:

Because of its antihistamine effect, Stugeron may prevent otherwise positive reactions to dermal reactivity indicators if used up to 4 days prior to skin testing. (See section 4.5).

 

Use of cinnarizine should be avoided in porphyria.

 

There have been no specific studies in hepatic or renal dysfunction. Stugeron should be used with care in patients with hepatic or renal insufficiency.

 

Patients with rare hereditary problems of galactose intolerance, fructose intolerance, LAPP lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

 

Avoid alcoholic drink.

 

Warning:  Do not exceed the stated dose.


Section 4.5:

added:

Diagnostic interference:

Because of its antihistamine effect, Stugeron may prevent otherwise positive reactions to dermal reactivity indicators if used up to 4 days prior to skin testing.


Section 4.6:

'Fertility' added to title.

Section 4.9:

Deleted:

Within the first hour after ingestion, gastric lavage may be performed.

Updated on 26/11/2010 and displayed until 21/01/2014
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
Date of revision of text on the SPC:   23-Nov-2010
Legal Category:   Supply through pharmacy only

Free-text change information supplied by the pharmaceutical company

Section 4.8:

Side effects listed in table along with frequency

Section 5.1:

ATC code added

Section 5.2

More detiled information added for Distribution, Metabolism and Elimination

Section 5.3
Information added where previously no information was available.
Updated on 25/03/2010 and displayed until 26/11/2010
Reasons for adding or updating:
  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   12-Mar-2010
Legal Category:   Supply through pharmacy only

Free-text change information supplied by the pharmaceutical company

Section 6.3: Shelf life chnaged from 5 to 3 years
Updated on 31/08/2009 and displayed until 25/03/2010
Reasons for adding or updating:
  • New SPC for new product
Date of revision of text on the SPC:  
Legal Category:   Supply through pharmacy only

Free-text change information supplied by the pharmaceutical company

None provided

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Cinnarizine